Diana Luftner
Berlin, BE 10117, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 25, 2021
Neoadjuvant and adjuvant end-points in health technology assessment in oncology.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 22, 2020
Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.
Journal: Targeted oncology
Published: October 20, 2020
Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.
Journal: Targeted oncology
Published: August 05, 2020
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry.
Journal: Cancers
Published: October 28, 2018
Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry.
Journal: Breast (Edinburgh, Scotland)
Published: June 16, 2017
Prescription pattern of aromatase inhibitors for the adjuvant therapy of breast cancer in Germany - results of the second survey among gynaecologists and medical oncologists.
Journal: Onkologie
Published: February 13, 2008
Clinical value of bisphosphonates in cancer therapy.
Journal: Anticancer research
Published: July 26, 2007
Pegfilgrastim -- rational drug design for the management of chemotherapy-induced neutropenia.
Journal: Onkologie
Published: September 01, 2005
Nuclear matrix proteins as biomarkers for breast cancer.
Journal: Expert review of molecular diagnostics
Published: April 20, 2002
Showing 1-11 of 11
Last Updated: 09/26/2026